Last 12 months
Inside the activity.
0 purchase rows · 78 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 35 |
| Mar 2026 | 0 | 13 |
| Apr 2026 | 0 | 9 |
| May 2026 | 0 | 12 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 3 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 12, 2017 Filed Dec 13, 2017 21:53 UTC |
Van Plew Daniel PEVP & General Mgr Industrial O
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001237899-17-000029 · edgardoc.xml · derivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-12-12 F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 21:53 UTC |
VAGELOS P ROYDirector · Chairman of the Board
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 74,390 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001237899-17-000028 · edgardoc.xml · derivative · entry 10 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,390 Underlying: Common Stock · 74,390 shares Expires 2027-12-12 F4 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 21:52 UTC |
STAHL NEILEVP Research and Development
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001237899-17-000027 · edgardoc.xml · derivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-12-12 F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 21:52 UTC |
Terifay Robert JEVP Commercial
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 32,300 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001237899-17-000026 · edgardoc.xml · derivative · entry 1 Terifay Robert J · CIK 0001391382 · EVP Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,300 Underlying: Common Stock · 32,300 shares Expires 2027-12-12 F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 21:52 UTC |
Landry Robert ESVP Finance & CFO
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 23,337 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001237899-17-000025 · edgardoc.xml · derivative · entry 1 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,337 Underlying: Common Stock · 23,337 shares Expires 2027-12-12 F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 21:53 UTC |
VAGELOS P ROYDirector · Chairman of the Board
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 153,969 | $0.00 Strike: $21.92 | $0.00 |
DisclosureSEC source: 0001237899-17-000028 · edgardoc.xml · derivative · entry 9 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 153,969 shares Expires 2017-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 21:53 UTC |
VAGELOS P ROYDirector · Chairman of the Board
|
Tax withholdingCommon Stock | 74,860 | $383.29 | $28,693,089.40 |
DisclosureSEC source: 0001237899-17-000028 · edgardoc.xml · nonDerivative · entry 3 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,847 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 21:53 UTC |
VAGELOS P ROYDirector · Chairman of the Board
|
Tax withholdingCommon Stock | 8,805 | $383.29 | $3,374,868.45 |
DisclosureSEC source: 0001237899-17-000028 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,707 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 21:53 UTC |
VAGELOS P ROYDirector · Chairman of the Board
|
Exercise / conversionCommon Stock | 153,969 | $21.92 | $3,375,000.48 |
DisclosureSEC source: 0001237899-17-000028 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 483,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 07, 2017 Filed Dec 13, 2017 21:53 UTC |
VAGELOS P ROYDirector · Chairman of the Board
|
GiftCommon Stock | 91 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-17-000028 · edgardoc.xml · nonDerivative · entry 5 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 149,717 Read SEC document |
| October 05, 2017 Filed Oct 5, 2017 20:18 UTC |
BROWN MICHAEL SDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $177.82 | $0.00 |
DisclosureSEC source: 0001237899-17-000024 · edgardoc.xml · derivative · entry 4 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2023-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| October 05, 2017 Filed Oct 5, 2017 20:18 UTC |
BROWN MICHAEL SDirector
|
SaleCommon Stock | 1,500 | $475.00 | $712,500.00 |
DisclosureSEC source: 0001237899-17-000024 · edgardoc.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| October 05, 2017 Filed Oct 5, 2017 20:18 UTC |
BROWN MICHAEL SDirector
|
Exercise / conversionCommon Stock | 1,500 | $177.82 | $266,730.00 |
DisclosureSEC source: 0001237899-17-000024 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| October 03, 2017 Filed Dec 13, 2017 21:53 UTC |
VAGELOS P ROYDirector · Chairman of the Board
|
GiftCommon Stock | 477 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-17-000028 · edgardoc.xml · nonDerivative · entry 4 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 149,808 Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 20:00 UTC |
BAKER CHARLES ADirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $18.61 | $0.00 |
DisclosureSEC source: 0001237899-17-000023 · edgardoc.xml · derivative · entry 3 BAKER CHARLES A · CIK 0001225470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 20:00 UTC |
BAKER CHARLES ADirector
|
SaleCommon Stock | 2,000 | $450.00 | $900,000.00 |
DisclosureSEC source: 0001237899-17-000023 · edgardoc.xml · nonDerivative · entry 2 BAKER CHARLES A · CIK 0001225470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 20:00 UTC |
BAKER CHARLES ADirector
|
Exercise / conversionCommon Stock | 2,000 | $18.61 | $37,220.00 |
DisclosureSEC source: 0001237899-17-000023 · edgardoc.xml · nonDerivative · entry 1 BAKER CHARLES A · CIK 0001225470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 06, 2017 Filed Sep 6, 2017 21:06 UTC |
Landry Robert ESVP Finance & CFO
|
SaleCommon Stock | 100 | $499.69 | $49,969.00 |
DisclosureSEC source: 0001237899-17-000021 · edgardoc.xml · nonDerivative · entry 10 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,099 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 06, 2017 Filed Sep 6, 2017 21:06 UTC |
Landry Robert ESVP Finance & CFO
|
SaleCommon Stock | 100 | $498.25 | $49,825.00 |
DisclosureSEC source: 0001237899-17-000021 · edgardoc.xml · nonDerivative · entry 9 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,199 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 06, 2017 Filed Sep 6, 2017 21:06 UTC |
Landry Robert ESVP Finance & CFO
|
SaleCommon Stock | 100 | $496.86 | $49,686.00 |
DisclosureSEC source: 0001237899-17-000021 · edgardoc.xml · nonDerivative · entry 8 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,299 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 06, 2017 Filed Sep 6, 2017 21:06 UTC |
Landry Robert ESVP Finance & CFO
|
SaleCommon Stock | 74 | $496.52 | $36,742.48 |
DisclosureSEC source: 0001237899-17-000021 · edgardoc.xml · nonDerivative · entry 7 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,399 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 06, 2017 Filed Sep 6, 2017 21:06 UTC |
Landry Robert ESVP Finance & CFO
|
SaleCommon Stock | 100 | $496.51 | $49,651.00 |
DisclosureSEC source: 0001237899-17-000021 · edgardoc.xml · nonDerivative · entry 6 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,473 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 21:06 UTC |
Landry Robert ESVP Finance & CFO
|
SaleCommon Stock | 89 | $501.88 | $44,667.32 |
DisclosureSEC source: 0001237899-17-000021 · edgardoc.xml · nonDerivative · entry 5 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,573 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 21:06 UTC |
Landry Robert ESVP Finance & CFO
|
SaleCommon Stock | 100 | $500.33 | $50,033.00 |
DisclosureSEC source: 0001237899-17-000021 · edgardoc.xml · nonDerivative · entry 4 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,662 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 21:06 UTC |
Landry Robert ESVP Finance & CFO
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $272.70 | $0.00 |
DisclosureSEC source: 0001237899-17-000021 · edgardoc.xml · derivative · entry 12 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,000 Underlying: Common Stock · 3,000 shares Expires 2023-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 21:06 UTC |
Landry Robert ESVP Finance & CFO
|
Tax withholdingCommon Stock | 706 | $501.29 | $353,910.74 |
DisclosureSEC source: 0001237899-17-000021 · edgardoc.xml · nonDerivative · entry 3 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,762 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 21:06 UTC |
Landry Robert ESVP Finance & CFO
|
Tax withholdingCommon Stock | 1,631 | $501.29 | $817,603.99 |
DisclosureSEC source: 0001237899-17-000021 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,468 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 21:06 UTC |
Landry Robert ESVP Finance & CFO
|
Exercise / conversionCommon Stock | 3,000 | $272.70 | $818,100.00 |
DisclosureSEC source: 0001237899-17-000021 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 20:04 UTC |
Landry Robert ESVP Finance & CFO
|
SaleCommon Stock | 127 | $497.69 | $63,206.63 |
DisclosureSEC source: 0001708138-17-000021 · edgardoc.xml · nonDerivative · entry 7 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,099 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 20:04 UTC |
Landry Robert ESVP Finance & CFO
|
SaleCommon Stock | 100 | $497.42 | $49,742.00 |
DisclosureSEC source: 0001708138-17-000021 · edgardoc.xml · nonDerivative · entry 6 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,226 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 20:04 UTC |
Landry Robert ESVP Finance & CFO
|
SaleCommon Stock | 100 | $489.56 | $48,956.00 |
DisclosureSEC source: 0001708138-17-000021 · edgardoc.xml · nonDerivative · entry 5 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,326 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 20:04 UTC |
Landry Robert ESVP Finance & CFO
|
SaleCommon Stock | 100 | $487.88 | $48,788.00 |
DisclosureSEC source: 0001708138-17-000021 · edgardoc.xml · nonDerivative · entry 4 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,426 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 30, 2017 Filed Sep 1, 2017 20:04 UTC |
Landry Robert ESVP Finance & CFO
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $272.70 | $0.00 |
DisclosureSEC source: 0001708138-17-000021 · edgardoc.xml · derivative · entry 9 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 2,000 shares Expires 2023-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 30, 2017 Filed Sep 1, 2017 20:04 UTC |
Landry Robert ESVP Finance & CFO
|
Tax withholdingCommon Stock | 454 | $486.91 | $221,057.14 |
DisclosureSEC source: 0001708138-17-000021 · edgardoc.xml · nonDerivative · entry 3 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,526 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 30, 2017 Filed Sep 1, 2017 20:04 UTC |
Landry Robert ESVP Finance & CFO
|
Tax withholdingCommon Stock | 1,119 | $486.91 | $544,852.29 |
DisclosureSEC source: 0001708138-17-000021 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,980 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 30, 2017 Filed Sep 1, 2017 20:04 UTC |
Landry Robert ESVP Finance & CFO
|
Exercise / conversionCommon Stock | 2,000 | $272.70 | $545,400.00 |
DisclosureSEC source: 0001708138-17-000021 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 25, 2017 Filed Aug 29, 2017 21:00 UTC |
Sanofi10% owner
|
PurchaseCommon Stock | 2,557 | $487.01 | $1,245,286.62 |
DisclosureSEC source: 0001140361-17-033562 · form4.xml · nonDerivative · entry 9 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,880,537 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F12 · price: Purchase prices range from $486.92 to $487.57 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC ("Aventis"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,080,985 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| August 25, 2017 Filed Aug 29, 2017 21:00 UTC |
Sanofi10% owner
|
PurchaseCommon Stock | 2,681 | $485.99 | $1,302,949.65 |
DisclosureSEC source: 0001140361-17-033562 · form4.xml · nonDerivative · entry 8 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,877,980 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F11 · price: Purchase prices range from $485.86 to $486.79 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC ("Aventis"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,080,985 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| August 25, 2017 Filed Aug 29, 2017 21:00 UTC |
Sanofi10% owner
|
PurchaseCommon Stock | 5,723 | $485.28 | $2,777,256.30 |
DisclosureSEC source: 0001140361-17-033562 · form4.xml · nonDerivative · entry 7 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,875,299 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F10 · price: Purchase prices range from $484.86 to $485.85 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC ("Aventis"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,080,985 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| August 25, 2017 Filed Aug 29, 2017 21:00 UTC |
Sanofi10% owner
|
PurchaseCommon Stock | 2,000 | $484.21 | $968,420.00 |
DisclosureSEC source: 0001140361-17-033562 · form4.xml · nonDerivative · entry 6 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,869,576 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F9 · price: Purchase prices range from $483.70 to $484.63 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC ("Aventis"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,080,985 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| August 25, 2017 Filed Aug 29, 2017 21:00 UTC |
Sanofi10% owner
|
PurchaseCommon Stock | 4,485 | $482.87 | $2,165,687.20 |
DisclosureSEC source: 0001140361-17-033562 · form4.xml · nonDerivative · entry 5 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,867,576 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F8 · price: Purchase prices range from $482.49 to $483.45 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC ("Aventis"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,080,985 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| August 25, 2017 Filed Aug 29, 2017 21:00 UTC |
Sanofi10% owner
|
PurchaseCommon Stock | 1,302 | $481.63 | $627,080.18 |
DisclosureSEC source: 0001140361-17-033562 · form4.xml · nonDerivative · entry 4 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,863,091 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F7 · price: Purchase prices range from $481.47 to $482.09 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC ("Aventis"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,080,985 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| August 25, 2017 Filed Aug 29, 2017 21:00 UTC |
Sanofi10% owner
|
PurchaseCommon Stock | 21,360 | $480.75 | $10,268,796.50 |
DisclosureSEC source: 0001140361-17-033562 · form4.xml · nonDerivative · entry 3 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,861,789 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F6 · price: Purchase prices range from $480.44 to $481.32 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC ("Aventis"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,080,985 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| August 25, 2017 Filed Aug 29, 2017 21:00 UTC |
Sanofi10% owner
|
PurchaseCommon Stock | 28,586 | $479.93 | $13,719,316.14 |
DisclosureSEC source: 0001140361-17-033562 · form4.xml · nonDerivative · entry 2 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,840,429 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F5 · price: Purchase prices range from $479.43 to $480.39 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC ("Aventis"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,080,985 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| August 25, 2017 Filed Aug 29, 2017 21:00 UTC |
Sanofi10% owner
|
PurchaseCommon Stock | 3,684 | $479.19 | $1,765,340.38 |
DisclosureSEC source: 0001140361-17-033562 · form4.xml · nonDerivative · entry 1 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,811,843 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F3 · price: Purchase prices range from $478.42 to $479.39 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC ("Aventis"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,080,985 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| August 24, 2017 Filed Aug 25, 2017 21:00 UTC |
Sanofi10% owner
|
PurchaseCommon Stock | 6,960 | $488.57 | $3,400,475.04 |
DisclosureSEC source: 0001140361-17-033310 · form4.xml · nonDerivative · entry 19 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,808,159 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F22 · price: Purchase prices range from $488.04 to $488.82 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC ("Aventis"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| August 24, 2017 Filed Aug 25, 2017 21:00 UTC |
Sanofi10% owner
|
PurchaseCommon Stock | 8,860 | $487.55 | $4,319,721.35 |
DisclosureSEC source: 0001140361-17-033310 · form4.xml · nonDerivative · entry 18 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,801,199 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F21 · price: Purchase prices range from $487.02 to $488.01 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC ("Aventis"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| August 24, 2017 Filed Aug 25, 2017 21:00 UTC |
Sanofi10% owner
|
PurchaseCommon Stock | 6,920 | $486.63 | $3,367,454.69 |
DisclosureSEC source: 0001140361-17-033310 · form4.xml · nonDerivative · entry 17 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,792,339 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F20 · price: Purchase prices range from $486.01 to $486.95 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC ("Aventis"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| August 24, 2017 Filed Aug 25, 2017 21:00 UTC |
Sanofi10% owner
|
PurchaseCommon Stock | 5,724 | $485.55 | $2,779,308.81 |
DisclosureSEC source: 0001140361-17-033310 · form4.xml · nonDerivative · entry 16 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,785,419 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F19 · price: Purchase prices range from $485.00 to $485.98 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC ("Aventis"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| August 24, 2017 Filed Aug 25, 2017 21:00 UTC |
Sanofi10% owner
|
PurchaseCommon Stock | 8,982 | $484.27 | $4,349,687.09 |
DisclosureSEC source: 0001140361-17-033310 · form4.xml · nonDerivative · entry 15 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,779,695 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F18 · price: Purchase prices range from $483.93 to $484.74 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC ("Aventis"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.